Moxifloxacina Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacina Kabi, is a fluoroquinolone presented as an injection for intravenous use. It treats a range of serious bacterial infections in adult patients, including community‑acquired pneumonia, intra‑abdominal infections, skin and soft‑tissue infections, and acute bacterial sinusitis.

GNH USA supplies Moxifloxacina Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacin is a fluoroquinolone antibacterial that targets a broad spectrum of Gram‑negative and Gram‑positive bacteria.

Community‑acquired bacterial pneumonia: achieves clinical cure and microbiological eradication in adult patients. Complicated intra‑abdominal infections: provides effective bacterial clearance after surgical source control. Skin and soft tissue infections: resolves infection signs and prevents progression. Acute bacterial sinusitis: reduces symptoms and eliminates causative pathogens.

Moxifloxacina Kabi may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: loose stools, occasionally watery. - Headache: transient cranial pain. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: can precipitate ventricular arrhythmias. - Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Clostridioides difficile colitis: severe diarrhea with pseudomembranous colitis. - Hepatic failure: marked elevation of liver enzymes and jaundice.

Before initiating therapy, consider patient‑specific factors and monitor for potential complications. - Renal impairment: adjust dosing according to renal function and prescriber guidance. - History of tendon disorders: avoid use or discontinue promptly if symptoms arise. - QT prolongation risk: obtain baseline ECG and monitor cardiac rhythm during treatment. - Concomitant antacids or multivitamins: separate administration by at least 2 hours to prevent reduced absorption. - Pregnancy and lactation: prescribe only when benefits outweigh potential risks. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacina Kabi can interact with several medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Co‑administration with other fluoroquinolones: increased risk of cumulative toxicity. - Concurrent use of QT‑prolonging drugs (e.g., macrolides, antiarrhythmics): heightened arrhythmia risk. - Combination with NSAIDs: may amplify central nervous system stimulation and seizure risk.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce moxifloxacin absorption; separate dosing. - Warfarin: potential enhancement of anticoagulant effect; monitor INR closely. - Corticosteroids: increased likelihood of tendon rupture; observe for musculoskeletal symptoms.